These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 33386842)
1. Observation of an α-synuclein liquid droplet state and its maturation into Lewy body-like assemblies. Hardenberg MC; Sinnige T; Casford S; Dada ST; Poudel C; Robinson EA; Fuxreiter M; Kaminksi CF; Kaminski Schierle GS; Nollen EAA; Dobson CM; Vendruscolo M J Mol Cell Biol; 2021 Aug; 13(4):282-294. PubMed ID: 33386842 [TBL] [Abstract][Full Text] [Related]
2. α-synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease. Cooper JF; Spielbauer KK; Senchuk MM; Nadarajan S; Colaiácovo MP; Van Raamsdonk JM Exp Neurol; 2018 Dec; 310():58-69. PubMed ID: 30194957 [TBL] [Abstract][Full Text] [Related]
4. Targeting alpha-synuclein for the treatment of Parkinson's disease. Rohn TT CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285 [TBL] [Abstract][Full Text] [Related]
5. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Wakabayashi K; Tanji K; Mori F; Takahashi H Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486 [TBL] [Abstract][Full Text] [Related]
6. Distinct Effects of Familial Parkinson's Disease-Associated Mutations on α-Synuclein Phase Separation and Amyloid Aggregation. Xu B; Fan F; Liu Y; Liu Y; Zhou L; Yu H Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238596 [TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Olanow CW; Brundin P Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095 [TBL] [Abstract][Full Text] [Related]
8. The involvement of dityrosine crosslinking in α-synuclein assembly and deposition in Lewy Bodies in Parkinson's disease. Al-Hilaly YK; Biasetti L; Blakeman BJ; Pollack SJ; Zibaee S; Abdul-Sada A; Thorpe JR; Xue WF; Serpell LC Sci Rep; 2016 Dec; 6():39171. PubMed ID: 27982082 [TBL] [Abstract][Full Text] [Related]
9. The effects of pdr1, djr1.1 and pink1 loss in manganese-induced toxicity and the role of α-synuclein in C. elegans. Bornhorst J; Chakraborty S; Meyer S; Lohren H; Brinkhaus SG; Knight AL; Caldwell KA; Caldwell GA; Karst U; Schwerdtle T; Bowman A; Aschner M Metallomics; 2014 Mar; 6(3):476-90. PubMed ID: 24452053 [TBL] [Abstract][Full Text] [Related]
10. Liquid-liquid Phase Separation of α-Synuclein: A New Mechanistic Insight for α-Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis. Mukherjee S; Sakunthala A; Gadhe L; Poudyal M; Sawner AS; Kadu P; Maji SK J Mol Biol; 2023 Jan; 435(1):167713. PubMed ID: 35787838 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Lee VM; Trojanowski JQ Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225 [TBL] [Abstract][Full Text] [Related]
12. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933 [TBL] [Abstract][Full Text] [Related]
13. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro. Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243 [TBL] [Abstract][Full Text] [Related]
14. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Conway KA; Harper JD; Lansbury PT Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204 [TBL] [Abstract][Full Text] [Related]
15. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains. Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884 [TBL] [Abstract][Full Text] [Related]
16. [The mechanism of Lewy body formation in Parkinson's disease]. Wakabayashi K; Takahashi H Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441 [TBL] [Abstract][Full Text] [Related]
17. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease? Schulz-Schaeffer WJ Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328 [TBL] [Abstract][Full Text] [Related]
18. Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification. Ko WKD; Bezard E Exp Neurol; 2017 Dec; 298(Pt B):172-179. PubMed ID: 28764902 [TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of α-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. Kuwahara T; Tonegawa R; Ito G; Mitani S; Iwatsubo T J Biol Chem; 2012 Mar; 287(10):7098-109. PubMed ID: 22232559 [TBL] [Abstract][Full Text] [Related]
20. Retrogradely transmitted α-synuclein is taken up by the endophilin-independent endocytosis in the C. elegans neural circuit. Wang X; Shinkai Y; Doi M Biochem Biophys Res Commun; 2021 May; 552():176-182. PubMed ID: 33751935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]